Ospemifene Hormos.
Hormos Medical is developing the selective estrogen receptor modulator ospemifene, for the potential treatment of postmenopausal osteoporosis and urogenital atrophy. By November 2003, Hormos had advanced the drug into phase II/III testing for both indications.
Gennari
Luigi
L
Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scott, 53100-Siena, Italy. gennari@unisi.it
D000818:Animals; D002986:Clinical Trials as Topic; D020847:Estrogen Receptor Modulators / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use
D020847:Estrogen Receptor Modulators; D000960:Hypolipidemic Agents; D013629:Tamoxifen; C119141:Ospemifene